Health care stocks were softer late Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing 0.2%.
The iShares Biotechnology ETF (IBB) shed 0.6%.
In corporate news, Chimerix (CMRX) shares soared 224% a day after the company said it plans to submit a new drug application with the US Food and Drug Administration seeking accelerated approval for dordaviprone.
UniQure (QURE) shares surged 110% after Wells Fargo upgraded the company's stock to overweight from equalweight, with a $35 price target. The upgrade follows the company's announcement that it reached an agreement with the US Food and Drug Administration on elements of an accelerated approval pathway for its drug AMT-130, a potential treatment for Huntington's disease.
Walgreens Boots Alliance (WBA) shares surged 16%. The company is in talks to be acquired by private equity firm Sycamore Partners, The Wall Street Journal reported, citing people familiar with the matter.
CervoMed (CRVO) shares plunged 78% after the company said a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。